Femke C C Klouwer1,2, Sacha Ferdinandusse1, Henk van Lenthe1, Wim Kulik1, Ronald J A Wanders1, Bwee Tien Poll-The2, Hans R Waterham1, Frédéric M Vaz3. 1. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. 2. Department of Pediatric Neurology, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 3. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. f.m.vaz@amc.uva.nl.
Abstract
INTRODUCTION: Zellweger spectrum disorders (ZSD) are a group of genetic metabolic disorders caused by a defect in peroxisome biogenesis. This results in multiple metabolic abnormalities, including elevated very long-chain fatty acid (VLCFA) levels. Elevated levels of C26:0-lysophosphatidylcholine (C26:0-lysoPC) have been shown in dried blood spots (DBS) from ZSD patients. However, little is known about the sensitivity and specificity of this marker and C26:0-carnitine, another VLCFA-marker, in ZSD. We investigated C26:0-lysoPC and C26:0-carnitine as diagnostic markers for ZSD in DBS and fibroblasts. METHODS: C26:0-lysoPC levels in 91 DBS from 37 different ZSD patients were determined and compared to the levels in 209 control DBS. C26:0-carnitine levels were measured in 41 DBS from 29 ZSD patients and 97 control DBS. We measured C26:0-lysoPC levels in fibroblasts from 24 ZSD patients and 61 control individuals. RESULTS: Elevated C26:0-lysoPC levels (>72 nmol/L) were found in 86/91 ZSD DBS (n=33/37 patients) corresponding to a sensitivity of 89.2%. Median level was 567 nmol/l (range 28-3133 nmol/l). Consistently elevated C26:0-carnitine levels (>0.077 μmol/L) in DBS were found in 16 out of 29 ZSD patients corresponding to a sensitivity of 55.2%. C26:0-lysoPC levels were elevated in 21/24 ZSD fibroblast lines. DISCUSSION: C26:0-lysoPC in DBS is a sensitive and useful marker for VLCFA accumulation in patients with a ZSD. C26:0-carnitine in DBS is elevated in some ZSD patients, but is less useful as a diagnostic marker. Implementation of C26:0-lysoPC measurement in the diagnostic work-up when suspecting a ZSD is advised. This marker has the potential to be used for newborn screening for ZSD.
INTRODUCTION:Zellweger spectrum disorders (ZSD) are a group of genetic metabolic disorders caused by a defect in peroxisome biogenesis. This results in multiple metabolic abnormalities, including elevated very long-chain fatty acid (VLCFA) levels. Elevated levels of C26:0-lysophosphatidylcholine (C26:0-lysoPC) have been shown in dried blood spots (DBS) from ZSD patients. However, little is known about the sensitivity and specificity of this marker and C26:0-carnitine, another VLCFA-marker, in ZSD. We investigated C26:0-lysoPC and C26:0-carnitine as diagnostic markers for ZSD in DBS and fibroblasts. METHODS: C26:0-lysoPC levels in 91 DBS from 37 different ZSD patients were determined and compared to the levels in 209 control DBS. C26:0-carnitine levels were measured in 41 DBS from 29 ZSD patients and 97 control DBS. We measured C26:0-lysoPC levels in fibroblasts from 24 ZSD patients and 61 control individuals. RESULTS: Elevated C26:0-lysoPC levels (>72 nmol/L) were found in 86/91 ZSD DBS (n=33/37 patients) corresponding to a sensitivity of 89.2%. Median level was 567 nmol/l (range 28-3133 nmol/l). Consistently elevated C26:0-carnitine levels (>0.077 μmol/L) in DBS were found in 16 out of 29 ZSD patients corresponding to a sensitivity of 55.2%. C26:0-lysoPC levels were elevated in 21/24 ZSD fibroblast lines. DISCUSSION: C26:0-lysoPC in DBS is a sensitive and useful marker for VLCFA accumulation in patients with a ZSD. C26:0-carnitine in DBS is elevated in some ZSD patients, but is less useful as a diagnostic marker. Implementation of C26:0-lysoPC measurement in the diagnostic work-up when suspecting a ZSD is advised. This marker has the potential to be used for newborn screening for ZSD.
Authors: B H Vogel; S E Bradley; D J Adams; K D'Aco; R W Erbe; C Fong; A Iglesias; D Kronn; P Levy; M Morrissey; J Orsini; P Parton; J Pellegrino; C A Saavedra-Matiz; N Shur; M Wasserstein; G V Raymond; M Caggana Journal: Mol Genet Metab Date: 2015-02-12 Impact factor: 4.797
Authors: Walter C Hubbard; Ann B Moser; Silvia Tortorelli; Anita Liu; David Jones; Hugo Moser Journal: Mol Genet Metab Date: 2006-07-07 Impact factor: 4.797
Authors: Andrea Mignarri; Claudia Vinciguerra; Antonio Giorgio; Sacha Ferdinandusse; Hans Waterham; Ronald Wanders; Enrico Bertini; Maria Teresa Dotti; Antonio Federico Journal: JIMD Rep Date: 2012-01-29
Authors: Luc Régal; Merel S Ebberink; Nathalie Goemans; Ronald J A Wanders; Linda De Meirleir; Jacques Jaeken; Maarten Schrooten; Rudy Van Coster; Hans R Waterham Journal: Ann Neurol Date: 2010-08 Impact factor: 10.422
Authors: Kevin Berendse; Marc Engelen; Sacha Ferdinandusse; Charles B L M Majoie; Hans R Waterham; Frédéric M Vaz; Johannes H T M Koelman; Peter G Barth; Ronald J A Wanders; Bwee Tien Poll-The Journal: J Inherit Metab Dis Date: 2015-08-19 Impact factor: 4.982
Authors: Pablo Ranea-Robles; Kensey Portman; Aaron Bender; Kyung Lee; John Cijiang He; David J Mulholland; Carmen Argmann; Sander M Houten Journal: Kidney360 Date: 2021-09-30
Authors: Ritesh Kumar Baboota; Abhijit Babaji Shinde; Katleen Lemaire; Marc Fransen; Stefan Vinckier; Paul P Van Veldhoven; Frans Schuit; Myriam Baes Journal: Mol Metab Date: 2019-02-08 Impact factor: 7.422
Authors: Rinse W Barendsen; Inge M E Dijkstra; Wouter F Visser; Mariëlle Alders; Jet Bliek; Anita Boelen; Marelle J Bouva; Saskia N van der Crabben; Ellen Elsinghorst; Ankie G M van Gorp; Annemieke C Heijboer; Mandy Jansen; Yorrick R J Jaspers; Henk van Lenthe; Ingrid Metgod; Christiaan F Mooij; Elise H C van der Sluijs; A S Paul van Trotsenburg; Rendelien K Verschoof-Puite; Frédéric M Vaz; Hans R Waterham; Frits A Wijburg; Marc Engelen; Eugènie Dekkers; Stephan Kemp Journal: Front Cell Dev Biol Date: 2020-06-17
Authors: Malena Daich Varela; Priyam Jani; Wadih M Zein; Precilla D'Souza; Lynne Wolfe; Jennifer Chisholm; Christopher Zalewski; David Adams; Blake M Warner; Laryssa A Huryn; Robert B Hufnagel Journal: Am J Med Genet C Semin Med Genet Date: 2020-08-31 Impact factor: 3.359